Seeking Alpha

Needham still positive on Sarepta as competitive landscape is improved

  • Needham is apparently out reiterating a Buy rating on Sarepta Therapeutics (SRPT), price target is $57.
  • Chad Messer says "drisapersen's failure may lead to skepticism on the exon-skipping approach in general, [but Needham] remains confident in eteplirsen's efficacy and believes [the drisapersen news] improves the competitive situation."
  • See previous coverage
Comments (1)
  • pat walsh
    , contributor
    Comments (217) | Send Message
    Chad Messer.Dont let the results of SRPT positive results get in your way.
    23 Sep 2013, 09:11 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: